Baker Wendy S, Albright Kathleen J, Spratt Heidi, Berman Megan, Mann Peggy A, Unabia Jaime, Petersen John R
University of Texas Medical Branch, Department of Preventive Medicine and Community Health, Galveston, TX 77555-1150, United States.
University of Texas Medical Branch, Department of Internal Medicine, Galveston, TX 77555-1167, United States.
Data Brief. 2017 Nov 7;16:312-320. doi: 10.1016/j.dib.2017.11.020. eCollection 2018 Feb.
The data presented here was produced as part of an evaluation of the performance of the CoaguChek XS point-of-care coagulation analyzer, which is discussed in the research article "POCT PT INR - Is it adequate for Patient Care? A Comparison of the Roche Coaguchek XS vs. Stago Star vs. Siemens BCS in Patients Routinely Seen in an Anticoagulation Clinic" (Baker et al., in press) [1]. An effort to reconcile discrepancies in the patient INR result distributions from different central lab instruments (Stago Star and Siemens BCS) with the PT/INR line method is described (Poller et al., 2010, 2011; Ibrahim et al., 2011) [2], [3], [4]. While regression analysis of the ECAA Poller calibrant data provided a linear PT/INR line for all methods, Pearson's chi-squared and one-way repeated measures ANOVA analyses showed that central lab INR measurements continued to exhibit measurement site dependence after the PT/INR line correction was applied. According to paired t-test analysis, only the human thromboplastin dependent methods (CoaguChek XS and Siemens BCS both before and after PT/INR line correction) showed statistically significant agreement (-value >0.05).
此处呈现的数据是作为对CoaguChek XS即时凝血分析仪性能评估的一部分而产生的,这在研究文章《POCT PT INR——对患者护理是否足够?抗凝门诊中罗氏CoaguChek XS与思达高Star及西门子BCS的比较》(Baker等人,即将发表)[1]中有讨论。描述了一项努力,即通过PT/INR线性方法来协调来自不同中心实验室仪器(思达高Star和西门子BCS)的患者INR结果分布中的差异(Poller等人,2010年、2011年;Ibrahim等人,2011年)[2]、[3]、[4]。虽然对欧洲临床化学与检验医学学会(ECAA)Poller校准数据的回归分析为所有方法提供了一条线性PT/INR线,但Pearson卡方检验和单向重复测量方差分析表明,在应用PT/INR线校正后,中心实验室INR测量仍表现出测量位点依赖性。根据配对t检验分析,只有依赖人凝血活酶的方法(PT/INR线校正前后的CoaguChek XS和西门子BCS)显示出统计学上的显著一致性(p值>0.05)。